Targeted therapeutic strategies aimed at these critical nodes, such as inhibiting CDK4 or cyclin D1 activity or restoring RB1 function, are expected to offer new therapeutic avenues for lung cancer patients (27, 28). This evidence concerns the gene CDK4 and lung cancer.